Breast Cancer Research and Treatment

, Volume 32, Issue 1, pp 67–71 | Cite as

Heat shock proteins and drug resistance

  • Suzanne A. W. Fuqua
  • Steffi Oesterreich
  • Susan G. Hilsenbeck
  • Daniel D. Von Hoff
  • John Eckardt
  • C. Kent Osborne
Article

Summary

Heat shock proteins (hsp's) are induced in cells when exposed to different environmental stressful conditions. We have found that breast cancer cells sometimes express high levels of several hsp's, which may both augment the aggressiveness of these tumors and make them more resistant to treatment. We have shown that hsp70 is an ominous prognostic sign as detected by Western blot assays in node-negative breast tumors, and that hsp27 increases specific resistance to doxorubicin in breast cancer cell lines. These findings have direct clinical application, and suggest that modulating hsp expression may be a therapeutic target for reversal of hsp-associated detrimental cellular effects.

Key words

doxorubicin drug resistance heat shock hsp27 hsp70 prognosis stress response 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Edwards DP, Adams DJ, Savage N, McGuire WL: Estrogen induced synthesis of specific proteins in human breast cancer cells. Biochem Biophys Res Commun 93:804–812, 1980.Google Scholar
  2. 2.
    Adams DJ, Hajj H, Bitar KG, Edwards DP, McGuire WL: Purification of an estrogen regulated breast cancer protein by monoclonal antibody affinity chromatography. Endocrinol 113:415–417, 1983.Google Scholar
  3. 3.
    Fuqua SAW, Blum-Salingaros M, McGuire WL: Induction of the estrogen-regulated “24K” protein by heat shock. Cancer Res 49:4126–4129, 1989.Google Scholar
  4. 4.
    Moretti-Rojas I, Fuqua SAW, Montgomery RA III, McGuire WL: A cDNA for the estrogen-regulated 24K protein-control of mRNA levels in MCF-7 cells. Breast Cancer Res Treat 11:155–163, 1988.Google Scholar
  5. 5.
    Miron T, Van Compernolle K, van De Kerckhove J, Wilchek M, Geiger B: A 25-kD inhibitor of actin polymerization is a low molecular mass heat shock protein. J Cell Biol 114:255–261, 1991.Google Scholar
  6. 6.
    Mendelsohn ME, Zhu Y, O'Neill S: The 29-kDa proteins phosphorylated in thrombin-activated human platelets are forms of the estrogen receptor-related 27-kDa heat shock protein. Proc Natl Acad Sci USA 88:11212–11216, 1991.Google Scholar
  7. 7.
    Ciocca DR, Luque EH: Immunological evidence for the identity between the hsp27 estrogen-regulated heat shock protein and the p29 estrogen receptor-associated protein in breast and endometrial cancer. Breast Cancer Res Treat 20:33–42, 1991.Google Scholar
  8. 8.
    Gaestel M, Gross B, Benndorf R, Strauss M, Schunk W-H, Kraft R, Otto A, Bohm H, Stahl J, Drabsch H, Bielka H: Molecular cloning, sequence and expression in Escherichia coli of the 25-kDa growth-related protein of Ehrlich ascites tumor and its homology to mammalian stress proteins. Eur J Biochem 179:209–213, 1989.Google Scholar
  9. 9.
    Ciocca DR, Adams DJ, Edwards DP, Bjercke RJ, McGuire WL: Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells. Cancer Res 43:1204–1210, 1983.Google Scholar
  10. 10.
    Horne GM, Angus B, Wright C, Needham G, Nicholson S, Harris AL, Innes B, Horne CHW: Relationship between oestrogen receptor, epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer. J Pathol 155:143–150, 1988.Google Scholar
  11. 11.
    Ciocca DR, Adams DJ, Edwards DP, Bjercke RJ, McGuire WL: Immunohistochemical detection of an estrogen regulated protein by monoclonal antibodies. Cancer Res 42:4256–4258, 1982.Google Scholar
  12. 12.
    Seymour L, Bezwoda WR, Meyer K, Behr C: Detection of P24 protein in human breast cancer: influence of receptor status and oestrogen exposure. Br J Cancer 61:886–890, 1990.Google Scholar
  13. 13.
    Chamness GC, Ruiz A, Fulcher L, Clark G, Fuqua SAW, McGuire WL: Estrogen-inducible heat shock protein hsp27 predicts recurrence in node-negative breast cancer. Proc AACR 30:252, 1989.Google Scholar
  14. 14.
    Tandon AK, Clark GM, Chamness GC, Fuqua SAW, Welch WJ, Riehl RM, McGuire WL: Heat shock/stress response proteins: Biological and clinical significance in breast cancer. Proc ASCO 9:23, 1990.Google Scholar
  15. 15.
    Thor A, Benz C, Moore D, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA: Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 83:170–178, 1991.Google Scholar
  16. 16.
    McGuire WL: Breast cancer prognostic factors: Evaluation guidelines (Editorial). J Natl Cancer Inst 83:154–155, 1991.Google Scholar
  17. 17.
    Ciocca DR, Clark GM, Tandon AK, Fuqua SAW, Welch WJ, McGuire WL: Heat shock protein hsp70 in axillary lymph node-negative breast cancer patients: Prognostic implications. J Natl Cancer Inst 85:570–574, 1993.Google Scholar
  18. 18.
    Stoll BA: Evaluation of cyclophosphamide dosage schedules in breast cancer. Br J Cancer 24:475–483, 1970.Google Scholar
  19. 19.
    Chlebowski RT, Pugh RP, Weiner JM, Bateman JR: Treatment of advanced breast carcinoma with 5-fluorouracil: A randomized comparison of two routes of delivery. Cancer 48:1711–1714, 1981.Google Scholar
  20. 20.
    Carter SK: Single and combination nonhormonal chemotherapy in breast cancer. Cancer 30:1543–1555, 1972.Google Scholar
  21. 21.
    Ahmann DL, Bisel HF, Eagan RT, et al: Controlled evaluation of Adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep 58:877–882, 1974.Google Scholar
  22. 22.
    Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and Adriamycin in patients with advanced breast cancer: A Southwest Oncology Group study. Cancer 38:13–20, 1976.Google Scholar
  23. 23.
    Li GC: Thermal biology and physiology in clinical hyperthermia: Current status and future needs. Cancer Res (S) 44:4886s-4893s, 1984.Google Scholar
  24. 24.
    Hahn GM, Li GC: Thermotolerance, thermoresistance, and thermosensitization.In: Moritomo RI, Tissières A, Georgopoulos C (eds) Stress Proteins in Biology and Medicine. Cold Spring Harbor Laboratory Press, 1990, pp 79–100.Google Scholar
  25. 25.
    Wallner K, Li GC: Adriamycin resistance, heat resistance and radiation response in Chinese hamster fibroblasts. J Rad Oncol Biol Phys 12:829–833, 1986.Google Scholar
  26. 26.
    Li GC: Heat shock proteins: Role in thermotolerance, drug resistance, and relationship to DNA topoisomerases. NCI Monogr 4:99–103, 1987.Google Scholar
  27. 27.
    Li GC, Hahn GM: Ethanol-induced tolerance to heat and to adriamycin. Nature 274:699–701, 1978.Google Scholar
  28. 28.
    Donaldson SS, Gordon LF, Hahn GM: Protective effect of hyperthermia against the cytotoxicity of actinomycin D on Chinese hamster cells. Cancer Treat Rep 62:1489–1495, 1978.Google Scholar
  29. 29.
    Shen J, Hughes C, Chao C, Cai J, Bartels C, Gessner T, Subjeck J: Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci USA 84:3278–3282, 1987.Google Scholar
  30. 30.
    Huot J, Roy G, Lambert H, Chrètien P, Landry J: Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. Cancer Res 51:245–252, 1991.Google Scholar
  31. 31.
    Ciocca DR, Fuqua SAW, Lock-Lim S, Toft DO, Welch WJ, McGuire WL: Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52:3648–3654, 1992.Google Scholar
  32. 32.
    Oesterreich S, Weng C-N, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SAW: The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 53:4443–4448, 1993.Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Suzanne A. W. Fuqua
    • 1
  • Steffi Oesterreich
    • 1
  • Susan G. Hilsenbeck
    • 1
  • Daniel D. Von Hoff
    • 2
  • John Eckardt
    • 2
  • C. Kent Osborne
    • 1
  1. 1.Department of Medicine, Division of Medical OncologyUniversity of Texas Health Science CenterSan AntonioUSA
  2. 2.Cancer Therapy and Research CenterSan AntonioUSA

Personalised recommendations